{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:41:36Z","timestamp":1768322496371,"version":"3.49.0"},"reference-count":27,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the characteristics and associated disability of headache as an adverse event following vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>According to clinical trials and post\u2010licensure surveillance, headache is a common symptom of vaccines, yet systematic investigations of post\u2010licensure reports of this adverse event are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective database analysis study. We searched the Vaccine Adverse Events Reporting System (VAERS) database completed from July 1990 to June 2020 (a 30\u2010year period prior to the start of COVID\u201019 pandemic) to identify reports of headache. We evaluated epidemiological features, including event characteristics, patient demographics, and vaccine type.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In those aged 3\u2009years or older, headache was the fifth most reported adverse symptom, present in 8.1% (43,218\/536,120) of all reports. Of headache reports, 96.3% (41,635\/43,218) included the code \u201cheadache\u201d not further specified\n                      <jats:italic>.<\/jats:italic>\n                      Migraine was coded in 1973 cases, although almost one\u2010third (12,467\/41,808; 29.8%) of headache reports without a migraine code mention nausea or vomiting\n                      <jats:italic>.<\/jats:italic>\n                      The onset of symptoms was within 1 day of vaccination in over two\u2010thirds of cases. The majority of reports were classified as not serious; about one\u2010third involved emergency room or office visits. Of the 43,218 total headache reports, only a minority involved hospitalizations (2624; 6.1%) or permanent disability (1091; 2.5%), females accounted for 68.9% (29,771) and males for 29.5% (12,725), patients aged 6 to 59\u2009years represented 67.3% (29,112), and over one\u2010third of cases were reported after herpes zoster (8665; 20.1%) and influenza (6748; 15.6%) vaccinations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In a national surveillance system, headache was a commonly reported post\u2010vaccination adverse event; a small subset of reports was considered serious. The development of standardized vaccine\u2010related case definitions could be useful for better evaluating headache as an adverse event during vaccine development, and may reduce vaccine hesitancy especially in headache\u2010prone individuals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14458","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T07:48:31Z","timestamp":1674028111000},"page":"275-282","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Post\u2010vaccination headache reporting: Trends according to the Vaccine Adverse Events Reporting System"],"prefix":"10.1111","volume":"63","author":[{"given":"Alexandra N.","family":"Cocores","sequence":"first","affiliation":[{"name":"Department of Neurology University of Miami Miller School of Medicine  Miami Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Goadsby","sequence":"additional","affiliation":[{"name":"NIHR King's Clinical Research Facility &amp; Headache Group\u2010Wolfson CARD King's College London  London UK"},{"name":"Department of Neurology University of California, Los Angeles  Los Angeles California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teshamae S.","family":"Monteith","sequence":"additional","affiliation":[{"name":"Department of Neurology University of Miami Miller School of Medicine  Miami Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(94)90315-8"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200404000-00002"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30925-9"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.01.074"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-021-01076-w"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1201"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.09.018"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.01.080"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir970"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.08.069"},{"key":"e_1_2_10_12_1","unstructured":"MedDRA\u00aethe Medical Dictionary for Regulatory Activities.A Registered Trademark of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Accessed January2021.http:\/\/www.meddramsso.com"},{"key":"e_1_2_10_13_1","unstructured":"U.S. Food and Drug Administration.CFR\u2013Code of Federal Regulations Title 21 21CFR600.80.https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/cfrsearch.cfm?fr=600.80"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01400-4"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2001.041007646.x"},{"key":"e_1_2_10_16_1","first-page":"1","article-title":"Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Markowitz LE","year":"2014","journal-title":"MMWR Recomm Rep"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13281"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0132-6"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006697"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12707"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181dad5de"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.07.035"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.85.12.1706"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.09.021"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(01)00500-5"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211038654"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.43955"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14458","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.14458","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14458","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:23:13Z","timestamp":1762075393000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1111\/head.14458"],"URL":"https:\/\/doi.org\/10.1111\/head.14458","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,18]]},"assertion":[{"value":"2022-06-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}